All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Determinants of therapeutic lag in multiple sclerosis

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F21%3A10432955" target="_blank" >RIV/00216208:11110/21:10432955 - isvavai.cz</a>

  • Alternative codes found

    RIV/00064165:_____/21:10432955

  • Result on the web

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=heU1MzqaeE" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=heU1MzqaeE</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1177/1352458520981300" target="_blank" >10.1177/1352458520981300</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Determinants of therapeutic lag in multiple sclerosis

  • Original language description

    Background: A delayed onset of treatment effect, termed therapeutic lag, may influence the assessment of treatment response in some patient subgroups. Objectives: The objective of this study is to explore the associations of patient and disease characteristics with therapeutic lag on relapses and disability accumulation. Methods: Data from MSBase, a multinational multiple sclerosis (MS) registry, and OFSEP, the French MS registry, were used. Patients diagnosed with MS, minimum 1 year of exposure to MS treatment and 3 years of pre-treatment follow-up, were included in the analysis. Studied outcomes were incidence of relapses and disability accumulation. Therapeutic lag was calculated using an objective, validated method in subgroups stratified by patient and disease characteristics. Therapeutic lag under specific circumstances was then estimated in subgroups defined by combinations of clinical and demographic determinants. Results: High baseline disability scores, annualised relapse rate (ARR) &gt; 1 and male sex were associated with longer therapeutic lag on disability progression in sufficiently populated groups: females with expanded disability status scale (EDSS) &lt; 6 and ARR &lt; 1 had mean lag of 26.6 weeks (95% CI = 18.2-34.9), males with EDSS &lt; 6 and ARR &lt; 1 31.0 weeks (95% CI = 25.3-36.8), females with EDSS &lt; 6 and ARR &gt; 1 44.8 weeks (95% CI = 24.5-65.1), and females with EDSS &gt; 6 and ARR &lt; 1 54.3 weeks (95% CI = 47.2-61.5). Conclusions: Pre-treatment EDSS and ARR are the most important determinants of therapeutic lag.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30103 - Neurosciences (including psychophysiology)

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2021

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Multiple Sclerosis Journal

  • ISSN

    1352-4585

  • e-ISSN

  • Volume of the periodical

    27

  • Issue of the periodical within the volume

    12

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    14

  • Pages from-to

    1838-1851

  • UT code for WoS article

    000677275500001

  • EID of the result in the Scopus database

    2-s2.0-85099300704